A very rare cause of markedly elevated CA 19–9: Glucagon-like peptide-1 receptor agonists - 20/09/24
Abstract |
Aim |
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1-RAs) are commonly used to treat type 2 diabetes mellitus (T2DM). Various adverse reactions have been gradually reported. This case presents a rare phenomenon in which a GLP1-RA caused a marked elevation in carbohydrate antigen 19–9(CA 19–9) without evidence of a tumor.
Methods |
A mixed-methods approach was utilized, incorporating medical history obtained from regular outpatient consultations and follow-up visits, along with ancillary examinations derived from laboratory tests and imaging.
Results |
The use of a GLP1-RA for treating T2DM resulted in an increase in CA 19–9 without evidence of a tumor, which gradually normalized after discontinuation of the drug.
Conclusion |
GLP1-RAs may lead to elevated levels of tumor markers during the treatment of T2DM, necessitating monitoring during therapy. Antidiabetic management should be adjusted on an individual basis as needed.
Le texte complet de cet article est disponible en PDF.Keywords : Carbohydrate antigen 19–9, Case report, Glucagon-like peptide-1 receptor agonists, Type 2 diabetes mellitus
Plan
Vol 50 - N° 6
Article 101578- novembre 2024 Retour au numéro
Article précédent
- Discovery of a TRMT10A mutation in a case of atypical diabetes: Case report
- C. Samhani, B. Guerci, C. Larose
- Prevalence of NAFLD, MAFLD, and MASLD: NHANES 1999-2018
- Jie Pan, Feilong Wu, Mingtao Chen, Jinsen He, Yingying Gu, Lei Pei, Xuye Lai, Zhenfeng Zhang, Lili Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?